SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...

The presence of symptoms and signs of lymphoma in the ocular adnexa is significantly associated with risk of systemic disease, according to a British study. A significant association also exists for ...

Eleven studies that satisfied the eligibility criteria were included in the review. More than half (58.48%) of the patients with breast cancer delayed seeking medical help at health facilities, with a ...

A pilot study of interferon-alpha-2b dose reduction in melanoma: High dose interferon is not necessary for optimal activation of immune signal transduction. This is an ASCO Meeting Abstract from the ...

Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & ...

Data sources The search was conducted in four databases (MEDLINE, EMBASE, SCOPUS, SPORTDiscus) and restricted to studies published from 2019 to 6 January 2022. Eligibility criteria for selecting ...

CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer ...